News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
222 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17960)
Month
January (2883)
February (2030)
March (1769)
April (2200)
May (2664)
June (3162)
July (3087)
August (3801)
September (4260)
October (5136)
November (4629)
December (3503)
Day
1 (335)
2 (311)
3 (237)
4 (70)
6 (2)
7 (48)
8 (54)
9 (56)
10 (84)
11 (40)
13 (1)
14 (80)
15 (90)
16 (78)
17 (59)
18 (31)
20 (1)
21 (91)
22 (78)
23 (75)
24 (68)
25 (25)
26 (1)
28 (4)
29 (222)
30 (262)
31 (261)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
6
7
8
9
10
11
13
14
15
16
17
18
20
21
22
23
24
25
26
28
29
30
31
Drug Development
Nordic Nanovector Announces PARADIGME Trial Approved to Start in Norway
Nordic Nanovector ASA (OSE: NANO) announces that its pivotal PARADIGME Phase 2b trial with Betalutin® (177Lu-satetraxetan-lilotomab) in third-line (3L) follicular lymphoma (FL) patients has been approved by the Regional Committees for Medical and Health Research Ethics (REK) in Norway.
May 29, 2018
·
2 min read
Policy
Feldan Therapeutics awarded US Patent for the second generation of its Feldan Shuttle platform
Feldan Therapeutics, Inc. announced today the issuance of a new patent related to the refinement of the Feldan Shuttle platform.
May 29, 2018
·
1 min read
Previous
23 of 23